Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Simplified Protocol for Microsatellite Instability Evaluation in Iranian Patients at Risk for Lynch Syndrome Publisher Pubmed



Abdollahi Z1 ; Tabatabaiefar MA1, 2 ; Noruzi M3 ; Miar P1 ; Kazemi M1 ; Naimi A4 ; Emami MH5 ; Zeinalian M1, 2, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Pediatric Inherited Disease Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Biology, Faculty of Sciences, Shahid Chamran University, Ahvaz, Iran
  4. 4. Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Poursina Hakim Digestive Diseases Research Center, Isfahan, Iran
  6. 6. Ala Cancer Prevention and Control Center, Isfahan, Iran

Source: Lab Medicine Published:2022


Abstract

Objective: The most important tumor characteristic of Lynch syndrome (LS) is microsatellite instability (MSI). In the current study, BAT34c4 and BAT26 mononucleotide markers were evaluated as part of efforts to test a cost-effective panel for MSI testing in Iranian patients, comparing it with the Promega kit. Methods: Amsterdam II clinical criteria were used to identify patients at risk for LS. The MSI status of these patients was determined using BAT34c4 and BAT26 markers, as well as the Promega kit. The results of both methods were compared, and the sensitivity and specificity of new short tandem repeat (STR) markers were estimated using statistical formulas. Results: Of the 37 patients we studied who were at risk for LS, 27% showed MSI-high results, via the Promega kit. The same results were achieved for BAT34c4 and BAT26 separately. Conclusions: The novel 2-marker kit for MSI testing has similar accuracy as the Promega kit at a lower cost, due to fewer markers and a more economical labeling method. © 2021 American Society for Clinical Pathology, 2021. All rights reserved.
Experts (# of related papers)